Summary: Cosmos Health Inc. (NASDAQ: COSM) reported a stock issuance to Chief Executive Officer Grigorios Siokas on February 12, 2026, when 388,532 common shares moved to Mr. Siokas as part of a debt exchange. The filing with the Securities and Exchange Commission lists the per-share value at $0.3732, for a total consideration of $145,000. At the time the company’s shares trade near $0.40, and multiple balance-sheet and market indicators point to a stressed financial position.
Transaction details
The Form 4 filing indicates the transfer of 388,532 shares to Siokas was executed in exchange for debt the company owed to him. Following the completion of this debt-for-equity swap, Siokas is recorded as directly owning 8,861,914 shares of Cosmos Health Inc.
Per market data cited in the filing, COSM shares are trading at approximately $0.40. Over the trailing 12 months the stock has fallen by more than 41%, and it is down roughly 53% over the past six months. Valuation data noted in the filing show a Price/Book ratio of 0.57, a figure characterized in the filing as indicating the stock appears undervalued on that metric.
Balance-sheet markers
The company’s leverage and distress indicators are also included in the disclosure. A reported debt-to-equity ratio of 0.91 and an Altman Z-Score of -2.42 were cited in the filing, with the latter figure identified as consistent with financial distress.
Operational and commercial developments
- Cosmos Health’s Greek subsidiary, Cosmofarm, expanded its customer footprint by 20% in 2025, adding nearly 100 new pharmacy customers.
- The company reported a 12% increase in annual revenue per customer and a 14% improvement in profitability per customer.
- Cosmos Health entered a manufacturing agreement with Libytec Pharmaceutical S.A. for a product called PathMuscle, which combines a muscle relaxant and a pain reliever; production will be handled by Cosmos Health’s subsidiary, Cana Laboratories, and Libytec will hold exclusive distribution rights in Greece.
Regulatory and treasury actions
Cosmos Health disclosed it received a notice from Nasdaq for failing to maintain a minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company has 180 days from December 11, 2025 to regain compliance and has stated it would consider a reverse stock split if it becomes necessary to meet the listing standard.
Separately, the company announced a partnership with Prime Ledger LLC to modernize its financial operations. That multi-phase agreement includes management of a $300 million treasury facility and is described as intended to strengthen security, manage risk, and improve yield.
Shareholder and market context
The filing characterizes Cosmos Health as a micro-cap company with an approximate market value of $13 million. The company is not currently profitable, though the filing states analysts expect the company to reach profitability during the current year.
Conclusion: The transfer of shares to CEO Grigorios Siokas through a debt exchange converts creditor exposure into equity ownership while the company balances operational growth initiatives in Greece, a manufacturing partnership, a technology-driven treasury arrangement, and a Nasdaq compliance process. Financial ratios cited in the filing underscore existing leverage and solvency concerns.
Note: The article is based on the company’s Form 4 filing and the disclosures contained therein.